UBS AM’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.38B | Buy |
22,719,320
+1,281,734
| +6% | +$74.7M | 0.29% | 65 |
|
|
2025
Q4 | $1.16B | Sell |
21,437,586
-351,360
| -2% | -$16.9M | 0.24% | 74 |
|
|
2025
Q3 | $983M | Sell |
21,788,946
-3,420,584
| -14% | -$160M | 0.21% | 91 |
|
|
2025
Q2 | $1.17B | Buy |
25,209,530
+2,583,486
| +11% | +$127M | 0.24% | 90 |
|
|
2025
Q1 | $1.38B | Buy |
22,626,044
+354,302
| +2% | +$20.7M | 0.35% | 54 |
|
|
2024
Q4 | $1.26B | Buy |
22,271,742
+3,196,919
| +17% | +$179M | 0.29% | 57 |
|
|
2024
Q3 | $987M | Buy |
19,074,823
+3,002,418
| +19% | +$141M | 0.25% | 72 |
|
|
2024
Q2 | $667M | Buy |
16,072,405
+3,877,323
| +32% | +$173M | 0.19% | 93 |
|
|
2024
Q1 | $661M | Buy |
12,195,082
+696,680
| +6% | +$35.5M | 0.24% | 77 |
|
|
2023
Q4 | $590M | Buy |
11,498,402
+415,739
| +4% | +$21.8M | 0.23% | 78 |
|
|
2023
Q3 | $643M | Sell |
11,082,663
-87,492
| -0.8% | -$5.36M | 0.29% | 66 |
|
|
2023
Q2 | $774M | Hold |
11,170,155
| – | – | 0.38% | 49 |
|
|
2023
Q1 | $774M | Buy |
11,170,155
+267,876
| +2% | +$18.9M | 0.38% | 49 |
|
|
2022
Q4 | $784M | Buy |
10,902,279
+675,732
| +7% | +$51M | 0.41% | 46 |
|
|
2022
Q3 | $727M | Buy |
10,226,547
+169,209
| +2% | +$12.3M | 0.41% | 42 |
|
|
2022
Q2 | $774M | Buy |
10,057,338
+455,505
| +5% | +$34.7M | 0.41% | 47 |
|
|
2022
Q1 | $701M | Buy |
9,601,833
+237,872
| +3% | +$16M | 0.3% | 64 |
|
|
2021
Q4 | $584M | Buy |
9,363,961
+332,905
| +4% | +$19.5M | 0.22% | 97 |
|
|
2021
Q3 | $534M | Sell |
9,031,056
-124,452
| -1% | -$8.2M | 0.22% | 96 |
|
|
2021
Q2 | $612M | Sell |
9,155,508
-314,034
| -3% | -$20.5M | 0.26% | 72 |
|
|
2021
Q1 | $598M | Buy |
9,469,542
+3,978
| +0% | +$248K | 0.26% | 73 |
|
|
2020
Q4 | $587M | Buy |
9,465,564
+837,646
| +10% | +$51.5M | 0.28% | 69 |
|
|
2020
Q3 | $520M | Buy |
8,627,918
+267,440
| +3% | +$16.1M | 0.28% | 66 |
|
|
2020
Q2 | $492M | Sell |
8,360,478
-1,550,281
| -16% | -$92.7M | 0.3% | 60 |
|
|
2020
Q1 | $552M | Buy |
9,910,759
+478,831
| +5% | +$29.3M | 0.4% | 53 |
|
|
2019
Q4 | $605M | Buy |
9,431,928
+2,624,680
| +39% | +$150M | 0.37% | 52 |
|
|
2019
Q3 | $345M | Buy |
6,807,248
+354,581
| +5% | +$16.7M | 0.23% | 84 |
|
|
2019
Q2 | $293M | Buy |
6,452,667
+542,204
| +9% | +$25.3M | 0.21% | 90 |
|
|
2019
Q1 | $282M | Buy |
5,910,463
+337,977
| +6% | +$16.8M | 0.21% | 97 |
|
|
2018
Q4 | $290M | Buy |
5,572,486
+467,668
| +9% | +$25.1M | 0.25% | 80 |
|
|
2018
Q3 | $317M | Sell |
5,104,818
-32,609
| -0.6% | -$1.94M | 0.24% | 86 |
|
|
2018
Q2 | $284M | Sell |
5,137,427
-174,046
| -3% | -$9.4M | 0.22% | 92 |
|
|
2018
Q1 | $336M | Buy |
5,311,473
+30,470
| +0.6% | +$1.96M | 0.27% | 75 |
|
|
2017
Q4 | $324M | Buy |
5,281,003
+387,094
| +8% | +$24.2M | 0.27% | 72 |
|
|
2017
Q3 | $312M | Buy |
4,893,909
+102,683
| +2% | +$6M | 0.28% | 72 |
|
|
2017
Q2 | $267M | Buy |
4,791,226
+434,072
| +10% | +$23.6M | 0.26% | 83 |
|
|
2017
Q1 | $237M | Sell |
4,357,154
-416,608
| -9% | -$22.9M | 0.24% | 90 |
|
|
2016
Q4 | $279M | Sell |
4,773,762
-734,141
| -13% | -$40.1M | 0.31% | 67 |
|
|
2016
Q3 | $297M | Buy |
5,507,903
+1,365,926
| +33% | +$87.7M | 0.32% | 68 |
|
|
2016
Q2 | $305M | Buy |
4,141,977
+174,695
| +4% | +$12.3M | 0.34% | 63 |
|
|
2016
Q1 | $253M | Sell |
3,967,282
-106,493
| -3% | -$6.72M | 0.29% | 77 |
|
|
2015
Q4 | $280M | Sell |
4,073,775
-869,497
| -18% | -$57.5M | 0.32% | 68 |
|
|
2015
Q3 | $293M | Sell |
4,943,272
-614,009
| -11% | -$39M | 0.32% | 69 |
|
|
2015
Q2 | $370M | Sell |
5,557,281
-28,101
| -0.5% | -$1.85M | 0.35% | 63 |
|
|
2015
Q1 | $360M | Sell |
5,585,382
-537,963
| -9% | -$33.7M | 0.35% | 64 |
|
|
2014
Q4 | $361M | Sell |
6,123,345
-88,581
| -1% | -$5M | 0.34% | 63 |
|
|
2014
Q3 | $318M | Buy |
6,211,926
+230,788
| +4% | +$11.5M | 0.32% | 72 |
|
|
2014
Q2 | $290M | Buy |
5,981,138
+114,321
| +2% | +$5.63M | 0.29% | 74 |
|
|
2014
Q1 | $305M | Buy |
5,866,817
+472,826
| +9% | +$25.2M | 0.33% | 67 |
|
|
2013
Q4 | $287M | Sell |
5,393,991
-172,204
| -3% | -$8.77M | 0.33% | 63 |
|
|
2013
Q3 | $258M | Buy |
5,566,195
+224,785
| +4% | +$9.87M | 0.32% | 73 |
|
|
2013
Q2 | $239M | Buy |
+5,341,410
| New | +$232M | 0.31% | 78 |
|
Other funds holding BMY
VCM
VPM
UBS AM's BMY Position: Q1 2026 in Review
UBS AM increased its Bristol-Myers Squibb (BMY) stake by 6% in Q1 2026, buying an estimated $74.7M and bringing the position to 22,719,320 shares worth $1.38B. The position accounts for 0.29% of the portfolio, ranked #65.
UBS AM first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.38B in Q1 2025. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- UBS AM held 22,719,320 shares of Bristol-Myers Squibb worth $1.38B as of Q1 2026.
- UBS AM bought 1,281,734 Bristol-Myers Squibb shares in Q1 2026, an estimated $74.7M.
- Bristol-Myers Squibb made up 0.29% of UBS AM's portfolio in Q1 2026, its #65 holding.
- UBS AM first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- UBS AM's Bristol-Myers Squibb position peaked at $1.38B in Q1 2025.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.